Archived explainer. For the current picture see today's EWTX page.
EDGEWISE THERAPEUTIC (EWTX) is down -9.12% in the latest session. Our newswire has captured 5 stories on EWTX across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
EWTX stock closed down 9.12% at $41.27 on July 13, 2026, as the company announced the sale of its muscular dystrophy assets to French pharmaceutical firm Servier. The transaction, which includes an upfront payment of $1.55 billion and potential milestone payments of up to $1.1 billion, has shifted the company's strategic focus to its cardiovascular pipeline. While the deal is expected to strengthen Edgewise's balance sheet, the stock reacted negatively to the divestiture of a high-profile late-stage asset.
According to PR Newswire, Edgewise Therapeutics completed the sale of its sevasemten compound and muscular dystrophy business to Servier, a move described as a strategic step to refocus the company on its cardiovascular pipeline. The press release emphasized that the upfront payment and milestone potential would provide Edgewise with financial flexibility and a stronger foundation for future growth.
The SEC 8-K filing on July 13 confirmed the completion of the asset disposition, disclosing the transaction under Item 2.01 and Regulation FD. TipRanks reported that the sale was announced on July 10, highlighting the transaction as a significant corporate development. Servier, through separate PR Newswire statements in both English and French, noted that the acquisition aligns with its strategic goals in rare neurological diseases.
The stock traded within a 52-week range of $12.30 to $48.40 and has a market cap of $4.9 billion. Despite the large upfront payment, Edgewise remains unprofitable with a trailing twelve-month EPS of -1.66. In the last 90 days, insiders have sold $7.9 million worth of shares, with the most recent filing on July 2. The AI sentiment across five coverage stories averaged 60/100, suggesting a mildly positive tone overall.
The stock's move reflects investor reaction to the strategic shift away from muscular dystrophy. Analysts from Oppenheimer, Guggenheim, and RBC Capital have maintained or initiated positive coverage, with price targets ranging from $51 to $59. The next key development will be how the market interprets Edgewise's refocused pipeline and the use of proceeds from the asset sale.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Edgewise Therapeutics ( ($EWTX) ) just unveiled an announcement. On July 10, 2026, Edgewise Therapeutics completed the sale of its sevasemten compound and muscular ...
Filed: 2026-07-13 AccNo: 0001104659-26-082902 Size: 226 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential...
Cette acquisition soutient l'ambition stratégique de Servier dans les maladies neurologiques rares avec le sevasemten, un traitement expérimental à un stade avancé de développement pour les dystrophies musculaires de Becker et de Duchenne. L'actif acquis et l'équipe d'experts renforcent...
Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical...
More on EWTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier EWTX move explainers: 2026-07-17 · 2026-07-14 · 2026-07-13